- Dimerix (DXB) submits a new patent family application for its flagship DMX-700 used to treat chronic obstructive pulmonary disease
- The application follows after the company’s recently announced 80 per cent reduction versus control in induced lung injury in mice
- Dimerix believes the new application is another key step in securing ownership over what is believed to be an important new drug discovery
- The new patent application bolsters an existing DMX-700 global patent application which was filed in September 2020
- Shares in DXB are up 3.13 per cent, trading at 16.5 cents as of 12:21 pm AEST
Dimerix (DXB) has submitted a new patent family application for its flagship DMX-700 used to treat chronic obstructive pulmonary disease (COPD).
The application followed after the company’s recently announced 80 per cent reduction versus control in induced lung injury in mice.
The company believes the new application is another key step in securing ownership over what is believed to be an important new drug discovery.
The new provisional patent application is numbered 2022902171 and titled “Dosage regimen for the treatment of COPD”. It has a priority date of August 2 and if granted, would expire post 2043.
In accordance with normal patent prosecution process, this patent application will not
become public until approximately 18 months after the priority date.
CEO and Managing Director Nina Webster called the application a very exciting and busy time for the company, with multiple activities adding significant value to the company.
“Our flagship Phase 3 program in FSGS is progressing well, and our second pipeline candidate, DMX-700 has demonstrated some very encouraging pre-clinical data,” Dr Webster said.
“The DMX-700 study identified some very surprising outcomes, which we believe further strengthens our IP position moving forward.”
The new patent application bolsters the existing DMX-700 global patent application PCT number PCT/AU2020/050987, which was filed in September 2020.
The DMX-700 compounds individually have a known safety profile in human studies, meaning the drug may potentially move directly into clinical studies, subject to regulatory approvals.
Dimerix said the clinical trial will now be designed, along with any further required nonclinical safety studies, with the initial clinical study expected to commence first half 2023.
Shares in Dimerix were up 3.13 per cent, trading at 16.5 cents as of 12:21 pm AEST.